Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients

From: Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study

Characteristics

Overall

Schizophrenia

Bipolar

p

(n = 903)

(n = 612)

(n = 291)

Gender, n (%) females

405 (44.9)

231 (37.7)

174 (59.8)

<0.001

Age (years); mean (SD)

40.9 (13.1)

39.2 (12.7)

44.6 (13.1)

<0.001

Insight

    

SUM1 total score, mean (SD)

2.3 (1.3)

2.5 (1.3)

1.9 (1.2)

<0.001

SUM2 total score, mean (SD)

2.1 (1.2)

2.3 (1.3)

1.9 (1.1)

<0.001

SUM3 total score, mean (SD)

2.0 (1.0)

2.1 (1.0)

1.8 (1.0)

<0.001

Medication adherence

    

MARS total score, mean (SD)

6.0 (2.8)

5.8 (2.7)

6.5 (2.8)

<0.001

Therapeutic alliance

    

WAI total score, mean (SD)

188.5 (27.0)

185.0 (27.4)

195.9 (24.5)

<0.001

Clinical severity

    

CGI total score, mean (SD)

4.0 (1.2)

4.0 (1.1)

3.9 (1.4)

0.305

Global functioning

    

GAF total score, mean (SD)

54.0 (16.0)

51.9 (15.7)

58.4 (15.6)

<0.001

  1. CGI clinical global impression, GAF global assessment of functioning, MARS medication adherence rating scale, SUM1 unawareness of having a mental disorder, SUM2 unawareness of response to medication, SUM3 unawareness of the need of medication, WAI working alliance inventory